Pharmafile Logo
Pharmafocus logo
Advanced Search

psoriasis

Showing 15 posts of 67 posts found.

Janssen’s Tremfya gets go-ahead from NICE in plaque psoriasis

May 11, 2018
Medical Communications, Sales and Marketing Janssen, NICE, Tremfya, UK, pharma, psoriasis

NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the …

News
janssen_latest_logo_on_sign

Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

February 19, 2018
Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …

News
vanilla-flower-542019_960_720

Vanilla compound found to prevent psoriasis

December 5, 2017
Manufacturing and Production, Research and Development biotech, drugs, pharma, pharmaceutical, psoriasis, vanilla

Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 …

News
novartis_outside_1

Novartis reveals strong long-term data Cosentyx in psoriasis of the hands and feet

December 1, 2017
Medical Communications, Research and Development Cosentyx, Novartis, palmoplantar psoriasis, pharma, psoriasis

Novartis has released new data for Consentyx (secukinumab) which it claims make the IL-17A inhibitor “the first biologic to show …

News

Psoriasis patients at greater risk of type 2 diabetes, study reveals

November 15, 2017
Research and Development diabetes, pharma, psoriasis, type 2 diabetes

Researchers at the University of Pennsylvania’s Perelman School of Medicine have discovered that people with psoriasis are more at risk …

News
janssen_latest_logo_on_sign

FDA expands Janssen’s Stelara to cover adolescent psoriasis patients

October 16, 2017
Sales and Marketing FDA, Janssen, Stelara, pharma, psoriasis

Janssen has announced that the FDA has approved an expanded indication for its psoriasis therapy Stelara (ustekinumab) for the treatment …

News

Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance

September 13, 2017
Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis

At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …

News
nice_new_london_office_internal_3_web

NICE recommends plaque psoriasis contender for NHS use

August 8, 2017
Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis

The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

July 21, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Teva, biotech, brexit, drugs, healthcare, pharma, pharmaceutical, psoriasis, top ten

The week was characterised by two big psoriasis approval stories, while Amgen’s osteoporosis treatment was knocked back. Novartis CEO Joe …

News
595427

Leo Pharma gets European approval for unique plaque psoriasis drug

July 20, 2017
Sales and Marketing EU, European Commission, biotech, drugs, pharma, pharmaceutical, psoriasis

The European Commission has announced that it has decided to approve Leo Pharma’s Kyntheum (brodalumab), making it the first and …

News
lavalbldg1806696_853705

Psoriasis drug Siliq will be cheapest in class, Valeant reveals

April 24, 2017
Sales and Marketing Siliq, Valeant, psoriasis

Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a …

News

Novartis’ psoriasis drug allows some patients to go into remission

March 21, 2017
Research and Development Cosentyx, Novartis, psoriasis

Novartis released data on patient’s reaction to Cosentyx for the treatment of psoriasis, finding that as many as 21% of …

News
janssen_latest_logo_on_sign_closer

Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

March 6, 2017
Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis

Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …

News
lavalbldg1806696_853705

FDA approves Valeant plaque psoriasis drug despite suicide concerns

February 16, 2017
Sales and Marketing FDA, Siliq, Valeant, psoriasis

The US Food and Drug Administration (FDA) has announced that it has approved Valeant Pharmaceutical’s injectable psoriasis treatment Siliq (brodalumab) …

News
amgen_hq

FDA approves first therapy for paediatric psoriasis treatment

November 7, 2016
Sales and Marketing Amgen, Enbrel, paediatric, psoriasis

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024